ClinicalTrials.gg
Not yet recruitingNCT06204653Updated Jan 12, 2024

Effect of High-flow Nasal Oxygenation on Gastric Insufflation in Children

An interventional study of HFNO group and MV group in Induction of General Anesthesia, sponsored by Ajou University School of Medicine. Not yet recruiting. Open to participants aged 1 Year to 6 Years. Per ClinicalTrials.gov, last updated 2024-01-12.

Sponsored by Ajou University School of Medicine · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
1 Year to 6 Years
Sex
All
01

Study summary

This is a randomized controlled study to compare the incidence of gastric insufflation when using high-flow nasal oxygenation and facemask ventilation in pediatric patients.

02

Conditions studied

  • Induction of General Anesthesia

Keywords

  • High flow nasal oxygenation
  • Facemask ventilation
  • Gastric insufflation
03

In context

Lead sponsor

Ajou University School of Medicine is the lead sponsor of 173 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients aged 1 to 6 years
  • physical classification 1 or 2
  • Scheduled for general anesthesia

Exclusion criteria

Exclusion Criteria:

  • Patients expected to have difficulty with mask ventilation
  • Patients with oropharyngeal facial deformity
  • Obese patients (>30 kg/m2)
  • Patients with an upper respiratory tract infection
  • Patients with a history of abdominal surgery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    High-flow nasal oxygenation group (HFNO group)

    Device: HFNO group

  • Active comparator
    Facemask ventilation group (MV group)

    Device: MV group

Interventions

  • DeviceHFNO group

    100% oxygen supplied in proportion to body weight using the Optiflow THRIVETM system while maintaining jaw thrust. (0-12 kg; 2 L/kg/min, 13-15 kg; 30 L/min, 16-30 kg; 35 L/min, 31-50 kg; 40 L/min)

    Also known as: Optiflow

  • DeviceMV group

    Mask ventilation using the one-hand E-C clamp technique and oropharyngeal airway (fresh gas flow 3 l/min, 100% O2, tidal volume 8-10 ml/kg, respiratory rate 20/min, I:E ratio 1:2, pop-off valve 13 cmH2O).

06

What researchers measure

Primary outcomes

  1. Incidence of gastric insufflation

    Incidence of gastric insufflation detected by gastric ultrasound (acoustic shadow phenomenon or comet-tail artifact in the antrum) or by epigastric auscultation (typical 'gurgling' or 'whoosh' sound)

    Time frame: From the start of anesthesia induction to 3 minutes after anesthesia induction

Secondary outcomes

  1. Gastric insufflation detected by ultrasound

    Presence of acoustic shadow phenomenon or comet-tail artifact detected by ultrasound

    Time frame: 3 minutes after anesthesia induction

  2. Gastric insufflation detected by auscultation

    Presence of 'gurgling' or 'whoosh' sound detected by auscultation of the epigastrium.

    Time frame: From the start of anesthesia induction to 3 minutes after anesthesia induction

  3. gastric antrum longitudinal diameter (D1)

    gastric antrum longitudinal diameter (D1) measured by ultrasound

    Time frame: 3 minutes after anesthesia induction

  4. gastric antrum anteroposterior diameter (D2)

    gastric antrum anteroposterior diameter (D2) measured by ultrasound

    Time frame: 3 minutes after anesthesia induction

  5. gastric antral cross-sectional area (CSA)

    gastric antral cross-sectional area (CSA) measured by ultrasound (CSA = (D1 Ⅹ D2 Ⅹ π)/4)

    Time frame: 3 minutes after anesthesia induction

Other outcomes

  1. MAP

    Mean arterial pressure

    Time frame: Every 1 minute during intervention (baseline, 1, 2, 3 min after induction)

  2. HR

    Heart rate

    Time frame: Every 1 minute during intervention (baseline, 1, 2, 3 min after induction)

  3. SpO2

    Peripheral oxygen saturation

    Time frame: Every 1 minute during intervention (baseline, 1, 2, 3 min after induction)

  4. TV

    Tidal volume in MV group

    Time frame: Every 1 minute during intervention (1, 2, 3 min after induction)

  5. PIP

    Peak airway pressure in MV group

    Time frame: Every 1 minute during intervention (1, 2, 3 min after induction)

  6. ETCO2

    End tidal CO2 in MV group

    Time frame: Every 1 minute during intervention (1, 2, 3 min after induction) and just after intubation

  7. Lowest SpO2

    Lowest peripheral oxygen saturation during intervention

    Time frame: From the start of anesthesia induction to completion of tracheal intubation

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Dec 2024, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2023
First posted
Jan 12, 2024
StartEst.
Jan 2, 2024
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Jan 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06204653
Responsible party
Jong Yeop Kim (Professor, Ajou University School of Medicine) — Principal investigator
First posted
Jan 12, 2024
Start date
Jan 2, 2024 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jan 12, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion